CF
INO icon

Centaurus Financial’s Inovio Pharmaceuticals INO Stock Holding History

Centaurus Financial’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-279
Closed -$13K – 1264
2018
Q2 		$13K Buy
+279
New +$15.4K ﹤0.01% 1446

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Centaurus Financial's INO Position: Q3 2018 in Review

Centaurus Financial sold out of Inovio Pharmaceuticals (INO) in Q3 2018, closing a stake of 279 shares — an estimated $13K sold.

Centaurus Financial first reported a position in INO in Q2 2018 and held it in 1 quarter. The position peaked at $13K in Q2 2018. 130 funds tracked by Wall St. Rank hold INO as of Q3 2018.

  • Centaurus Financial reported no remaining Inovio Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 279 Inovio Pharmaceuticals shares in Q3 2018, an estimated $13K.
  • Centaurus Financial first reported a position in Inovio Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Inovio Pharmaceuticals position peaked at $13K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.